ARMEN GARO H

SEC source: 0000899243-22-006140 · doc5.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,866,400

F1 · kind: This transaction is not a sale and involves a gift of securities to a charitable organization. These shares are subject to the IPO lock-up agreement.

SEC source: 0000899243-21-035844 · doc4.xml · derivative · entry 5

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 119,178 shares

Expires 2021-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035844 · doc4.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 770,773

F4 · price: Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035844 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 852,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.

SEC source: 0000899243-21-027363 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 733,702

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 2, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $5.52 is the closing price of our Common Stock on July 2, 2021, the payroll date for the pay period ending July 2, 2021.

SEC source: 0000899243-21-025019 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,023

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 18, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $5.26 is the closing price of our Common Stock on June 18, 2021, the payroll date for the pay period ending June 18, 2021.

SEC source: 0000899243-21-027363 · doc4.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900,000

Underlying: Common Stock · 1,900,000 shares

Expires 2030-12-17

F5 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-022383 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 607,211

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 4, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.03 is the closing price of our Common Stock on June 4, 2021, the payroll date for the pay period ending June 4, 2021.

SEC source: 0000899243-21-020399 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 603,541

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 21, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.19 is the closing price of our Common Stock on May 21, 2021, the payroll date for the pay period ending May 21, 2021.

SEC source: 0000899243-21-018729 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,011

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 7, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.07 is the closing price of our Common Stock on May 7, 2021, the payroll date for the pay period ending May 7, 2021.

SEC source: 0001745285-21-000019 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 595,194

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 23, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.05 is the closing price of our Common Stock on April 23, 2021, the payroll date for the pay period ending April 23, 2021.

SEC source: 0001745285-21-000018 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 590,345

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 9, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.785 is the closing price of our Common Stock on April 9, 2021, the payroll date for the pay period ending April 9, 2021.

SEC source: 0000899243-21-014724 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,700

F1 · security: All Agenus employees were given the option to receive their 2020 bonus awards in cash or Agenus stock. Dr. Armen, Dr. Buell and Ms. Klaskin have all chosen to receive their entire 2020 bonus award in Agenus stock rather than cash. The stock issued is fully-vested on the date of issuance, but is subject to a 6-month lockup restriction. In addition, Dr. Armen continues to receive his base salary in Agenus stock rather than cash

F2 · price: $2.87 is the fair market value of our Common Stock on April 2, 2021, the stock issuance date.

SEC source: 0001745285-21-000012 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,922

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 26, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.85 is the closing price of our Common Stock on March 26, 2021, the payroll date for the pay period ending March 26, 2021.

SEC source: 0001745285-21-000011 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,745

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 12, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.31 is the closing price of our Common Stock on March 12, 2021, the payroll date for the pay period ending March 12, 2021.

SEC source: 0001745285-21-000010 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 442,317

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 26, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.00 is the closing price of our Common Stock on February 26, 2021, the payroll date for the pay period ending February 26, 2021.

SEC source: 0001745285-21-000009 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 439,481

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 12, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan as are fully vested on the date of issuance.

F2 · price: $4.64 is the closing price of our Common Stock on February 12, 2021, the payroll date for the pay period ending February 12, 2021.

SEC source: 0001745285-21-000008 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 437,036

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount represented herein represents the net amount of Dr. Armen's salary for the pay period ending January 29, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.68 is the closing price of our Common Stock on January 29, 2021, the payroll date for the pay period ending January 29, 2021.

SEC source: 0001745285-21-000007 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,953

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 15, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.35 is the closing price of our Common Stock on January 15, 2021, the payroll date for the pay period ending January 15, 2021.

SEC source: 0001745285-21-000001 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,538

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the period ending December 31, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.18 is the closing price of our Common Stock on December 31, 2020, the payroll date for the pay period ending December 31, 2020.

SEC source: 0001745285-21-000002 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,567

F1 · security: As previously reported in Current Report on Form 8-K FILED with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 31, 2020. Such shares are issued in accordance with the Agenus 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.18 is the closing price of our Common Stock on December 31, 2020, the payroll date for the pay period ending December 31, 2020.

SEC source: 0001745285-20-000043 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,845

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 18, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan (the "2019 Plan") and are fully vested on the date of issuance.

F2 · price: $3.55 is the closing price of our Common Stock on December 18, 2020, the payroll date for the pay period ending December 18, 2020.

SEC source: 0001745285-20-000043 · primary_doc.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900,000

Underlying: Common Stock · 1,900,000 shares

Expires 2030-12-17

F5 · derivative.exercise_date: Stock Option awarded in accordance with the 2019 Plan. One-third of the Stock Option vests on December 17, 2021, with the remaining vesting in eight equal quarterly installments thereafter; provided Dr. Armen maintains a service relationship with the Company through each such vesting date and in the event of Dr. Armen's death, disability or retirement, all of the unvested options will vest in full and become exercisable, and each stock option will remain exercisable for the lesser of (a) three years from the date of such event or (b) the end of the 10-year term of each such stock option.

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 3

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,682

F4 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 4, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F5 · price: $3.33 is the closing price of our Common Stock on December 4, 2020, the payroll date for the pay period ending December 4, 2020.

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 704,046

F3 · security: Distribution from the Garo Armen 2018 2 Year AG GRAT to the beneficiaries of the remainder interest. This transaction does not represent a sale of Agenus Common Stock.

F7 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 600,000 shares of our Common Stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

SEC source: 0001745285-20-000041 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 735,146

F1 · security: Distribution from the Garo Armen 2018 2 Year AG GRAT to the beneficiaries of the remainder interest. This transaction does not represent a sale of Agenus Common Stock.

F2 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2018 2 Year AG GRAT, which after this transaction was the holder of 31,100 shares of our Common Stock.

F7 · ownership.nature: Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 600,000 shares of our Common Stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

SEC source: 0001745285-20-000040 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,645

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 20, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.65 is the closing price of our Common Stock on November 20, 2020, the payroll date for the pay period ending November 20, 2020.

SEC source: 0001745285-20-000039 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,496

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 6, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.82 is the closing price of our Common Stock on November 6, 2020, the payroll date for the pay period ending November 6, 2020.

SEC source: 0001745285-20-000038 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,627

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 23, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.94 is the closing price of our Common Stock on October 23, 2020, the payroll date for the pay period ending October 23, 2020.

SEC source: 0001745285-20-000036 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,876

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 9, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.35 is the closing price of our Common Stock on October 9, 2020, the payroll date for the pay period ending October 9, 2020.

SEC source: 0001745285-20-000032 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,479

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 25, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.02 is the closing price of our Common Stock on September 25, 2020, the payroll date for the pay period ending September 25, 2020.

SEC source: 0001745285-20-000031 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,803

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 11, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.99 is the closing price of our Common Stock on September 11, 2020, the payroll date for the pay period ending September 11, 2020.

SEC source: 0001745285-20-000030 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,841

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 28, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.28 is the closing price of our Common Stock on August 28, 2020, the payroll date for the pay period ending August 28, 2020.

SEC source: 0001745285-20-000029 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,389

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 14, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.71 is the closing price of our Common Stock on August 14, 2020, the payroll date for the pay period ending August 14, 2020.

SEC source: 0001745285-20-000028 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,405

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 31, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.04 is the closing price of our Common Stock on July 31, 2020, the payroll date for the pay period ending July 31, 2020.

SEC source: 0001745285-20-000027 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,544

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 17, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.60 is the closing price of our Common Stock on July 17, 2020, the payroll date for the pay period ending July 17, 2020.

SEC source: 0001745285-20-000026 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,439

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 3, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $4.02 is the closing price of our Common Stock on July 2, 2020, the payroll date for the pay period ending July 3, 2020.

SEC source: 0001745285-20-000018 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,763

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 19, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.83 is the closing price of our Common Stock on June 19, 2020, the payroll date for the pay period ending June 19, 2020.

SEC source: 0001745285-20-000011 · primary_doc.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,333

Underlying: Common Stock · 58,333 shares

Expires 2030-06-15

F1 · derivative.exercise_date: Option was granted on June 15, 2020 in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests on June 15, 2021; provided, however, that the unvested portion of such option shall vest in full upon Dr. Armen's death, disability or retirement.

SEC source: 0001745285-20-000009 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301,904

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 5, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.85 is the closing price of our Common Stock on June 5, 2020, the payroll date for the pay period ending June 5, 2020.

SEC source: 0001745285-20-000008 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,066

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 22, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.50 is the closing price of our Common Stock on May 22, 2020, the payroll date for the pay period ending May 22, 2020.

SEC source: 0001745285-20-000007 · primary_doc.xml · nonDerivative · entry 3

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,155

F3 · kind: Represents deposit into the Garo Armen 2020 2 Year AG GRAT.

SEC source: 0001745285-20-000007 · primary_doc.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 892,155

F2 · kind: Represents deposit into the Garo Armen 2018 2 Year AG GRAT.

SEC source: 0001745285-20-000007 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,051,155

F1 · kind: Represents a distribution from the Garo Armen 2018 2 Year AG GRAT.

SEC source: 0001745285-20-000006 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 892,155

F1 · security: As previously reported in Current Report on Form 8-K with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary in being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 8, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.53 is the closing price of our Common Stock on May 8, 2020, the payroll date for the pay period ending May 8, 2020.

SEC source: 0001745285-20-000005 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,112,282

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 24, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.79 is the closing price of our Common Stock on April 24, 2020, the payroll date for the pay period ending April 24, 2020.

SEC source: 0001745285-20-000004 · primary_doc.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,106,986

F1 · security: As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the amount of Dr. Armen's salary for the period ending April 10, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.50 is the closing price of our Common Stock on April 9, 2020, such amount represents the fair market value of our Common Stock on the payroll date for the pay period ending April 10, 2020.

SEC source: 0001493152-20-003037 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: PTIX Common Stock, Par Value $0.0001 · 300,000 shares

Expires 2030-02-21

SEC source: 0001745285-19-000020 · primary_doc.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Common Stock · 1,500,000 shares

Expires 2029-12-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting on December 24, 2020, and the balance vesting in equal quarterly installments thereafter; provided, however, that the unvested portion of such option shall vest in full upon Dr. Armen's death, disability or retirement.

SEC source: 0001745285-19-000018 · primary_doc.xml · nonDerivative · entry 5

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,075

F1 · kind: Represents shares donated to a charitable organization.